Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 3657cc39-5ccd-49af-8f85-b622acc243d9

AMJEVITA

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-06-25
Captured
2026-09-09T23:37:42.544548+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue AMJEVITA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting AMJEVITA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including AMJEVITA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue AMJEVITA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before AMJEVITA use and during therapy. Initiate treatment for latent TB prior to AMJEVITA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with AMJEVITA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with AMJEVITA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ].

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. AMJEVITA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. AMJEVITA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] . 1.7 Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis AMJEVITA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Full extracted label fields
application numbers
  1. BLA761024
boxed warning exact
  1. WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue AMJEVITA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting AMJEVITA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including AMJEVITA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue AMJEVITA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before AMJEVITA use and during therapy. Initiate treatment for latent TB prior to AMJEVITA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with AMJEVITA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with AMJEVITA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ].
brand names
  1. AMJEVITA
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c44bd5b-4464-40a4-8933-8680950f00f2
generic names
  1. ADALIMUMAB-ATTO
id
3657cc39-5ccd-49af-8f85-b622acc243d9
indications and usage exact
  1. 1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. AMJEVITA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. AMJEVITA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] . 1.7 Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis AMJEVITA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Amgen, Inc
    matched search terms
    1. tumor
    package ndcs
    1. 55513-411-01
    2. 55513-410-02
    3. 55513-410-01
    4. 55513-400-01
    5. 55513-400-02
    6. 55513-400-91
    7. 55513-413-01
    8. 55513-399-01
    9. 55513-479-01
    10. 55513-479-02
    11. 55513-480-01
    12. 55513-480-02
    product ndcs
    1. 55513-399
    2. 55513-411
    3. 55513-410
    4. 55513-400
    5. 55513-413
    6. 55513-479
    7. 55513-480
    8. 55513-482
    9. 55513-481
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
    1. Indications and Usage ( 1.8 , 1.9 ) 10/2025 Dosage and Administration ( 2.1 , 2.3 , 2.7 ) 10/2025 Warnings and Precautions, Autoimmunity ( 5.9 ) 10/2025
    record type
    complete_spl_indications_section_candidate
    routes
    1. SUBCUTANEOUS
    rxcuis
    1. 2627711
    2. 2627717
    3. 2627719
    4. 2627722
    5. 2627724
    6. 2627725
    7. 2634478
    8. 2634479
    9. 2663901
    10. 2663904
    11. 2663906
    12. 2663907
    source batch
    file
    /private/tmp/cancer-full-research/indications/raw/labels-00100.json
    meta
    disclaimer
    Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
    last updated
    2026-09-09
    results
    limit
    100
    skip
    100
    total
    830
    sha256
    fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
    url
    https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=100&sort=id%3Aasc
    source url
    https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
    spl effective date
    2026-06-25
    spl effective time
    20260625
    spl set id
    9c44bd5b-4464-40a4-8933-8680950f00f2
    spl version
    36
    substance names
    1. ADALIMUMAB
    uniis
    1. FYS6T7F842
    verification flags
    1. oncology_keyword_candidate_not_clinically_classified
    2. spl_text_not_verified_identical_to_latest_approved_label
    3. individual_indications_not_split_or_reconciled
    Drugs@FDA application source records
    1. application number
      BLA761024
      payload
      all indexed label documents
      1. Appl No
        761024
        Application Docs Date
        2017-09-12 00:00:00
        Application Docs ID
        49717
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        1
        Submission Type
        ORIG
      2. Appl No
        761024
        Application Docs Date
        2018-03-16 00:00:00
        Application Docs ID
        53040
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        3
        Submission Type
        SUPPL
      3. Appl No
        761024
        Application Docs Date
        2019-06-14 00:00:00
        Application Docs ID
        59067
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        4
        Submission Type
        SUPPL
      4. Appl No
        761024
        Application Docs Date
        2022-07-29 00:00:00
        Application Docs ID
        71667
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        10
        Submission Type
        SUPPL
      5. Appl No
        761024
        Application Docs Date
        2023-03-23 00:00:00
        Application Docs ID
        73830
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        12
        Submission Type
        SUPPL
      6. Appl No
        761024
        Application Docs Date
        2023-04-07 00:00:00
        Application Docs ID
        73962
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        11
        Submission Type
        SUPPL
      7. Appl No
        761024
        Application Docs Date
        2023-07-14 00:00:00
        Application Docs ID
        74762
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        17
        Submission Type
        SUPPL
      8. Appl No
        761024
        Application Docs Date
        2023-08-16 00:00:00
        Application Docs ID
        75088
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        15
        Submission Type
        SUPPL
      9. Appl No
        761024
        Application Docs Date
        2024-08-21 00:00:00
        Application Docs ID
        79457
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        19
        Submission Type
        SUPPL
      10. Appl No
        761024
        Application Docs Date
        2025-04-08 00:00:00
        Application Docs ID
        81841
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        23
        Submission Type
        SUPPL
      11. Appl No
        761024
        Application Docs Date
        2025-05-20 00:00:00
        Application Docs ID
        82229
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        21
        Submission Type
        SUPPL
      12. Appl No
        761024
        Application Docs Date
        2025-09-18 00:00:00
        Application Docs ID
        83387
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        22
        Submission Type
        SUPPL
      all submission records
      1. Appl No
        761024
        Review Priority
        Submission Class Code ID
        28
        Submission No
        26
        Submission Status
        AP
        Submission Status Date
        2025-10-16 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      2. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        23
        Submission Status
        AP
        Submission Status Date
        2025-04-07 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      3. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        22
        Submission Status
        AP
        Submission Status Date
        2025-09-17 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      4. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        21
        Submission Status
        AP
        Submission Status Date
        2025-05-20 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      5. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        19
        Submission Status
        AP
        Submission Status Date
        2024-08-20 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      6. Appl No
        761024
        Review Priority
        N/A
        Submission Class Code ID
        19
        Submission No
        17
        Submission Status
        AP
        Submission Status Date
        2023-07-12 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      7. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        15
        Submission Status
        AP
        Submission Status Date
        2023-08-14 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      8. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        12
        Submission Status
        AP
        Submission Status Date
        2023-03-22 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      9. Appl No
        761024
        Review Priority
        N/A
        Submission Class Code ID
        4
        Submission No
        11
        Submission Status
        AP
        Submission Status Date
        2023-04-06 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      10. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        10
        Submission Status
        AP
        Submission Status Date
        2022-07-28 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      11. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        4
        Submission Status
        AP
        Submission Status Date
        2019-06-13 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      12. Appl No
        761024
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        3
        Submission Status
        AP
        Submission Status Date
        2018-03-15 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      application number
      BLA761024
      approval interpretation
      Application linkage and approved submission are not indication-level current approval verification
      current indication status
      not_reconciled
      has approved submission record
      true
      latest approved submission date
      2025-10-16
      latest label selection rule
      max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
      latest posted label documents
      1. Appl No
        761024
        Application Docs Date
        2025-10-17 00:00:00
        Application Docs ID
        83800
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        26
        Submission Type
        SUPPL
      official application record
      Appl No
      761024
      Appl Public Notes
      Appl Type
      BLA
      Sponsor Name
      AMGEN INC
      openfda application present
      true
      products
      1. Active Ingredient
        ADALIMUMAB-ATTO
        Appl No
        761024
        Drug Name
        AMJEVITA
        Form
        INJECTABLE;INJECTION
        Product No
        001
        Reference Drug
        0
        Reference Standard
        Strength
        20MG/0.4ML
        marketing status
        1. Prescription
      2. Active Ingredient
        ADALIMUMAB-ATTO
        Appl No
        761024
        Drug Name
        AMJEVITA
        Form
        INJECTABLE;INJECTION
        Product No
        002
        Reference Drug
        0
        Reference Standard
        Strength
        40MG/0.8ML
        marketing status
        1. Prescription

    Source passages and status connections

    Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

    Passage 1 · positive indication candidate
    application numbers
    1. BLA761024
    brand names
    1. AMJEVITA
    classification reasons
    1. explicit_positive_indication_predicate
    2. tumor_or_malignant_hematology_words_in_positive_statement
    clinical review status
    pending
    content role
    positive_indication_candidate
    context span
    end
    508
    end exclusive
    true
    exact text
    1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
    label id
    3657cc39-5ccd-49af-8f85-b622acc243d9
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
    start
    0
    current approval status
    not_reconciled
    duplicate text group
    dup-7938d82684926060355b
    extraction review status
    automated_candidate_pending_source_review
    generic names
    1. ADALIMUMAB-ATTO
    id
    ind-span-ec9042d5226b51e1f916
    label id
    3657cc39-5ccd-49af-8f85-b622acc243d9
    positive predicate support span
    end
    83
    end exclusive
    true
    exact text
    is a tumor necrosis factor (TNF) blocker indicated
    label id
    3657cc39-5ccd-49af-8f85-b622acc243d9
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
    start
    33
    qualifier mentions
    1. context exact
      on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
      kind
      age
      polarity
      not_inferred
      span
      end
      250
      end exclusive
      true
      exact text
      adult patients
      label id
      3657cc39-5ccd-49af-8f85-b622acc243d9
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
      start
      236
    regulatory links
      schema version
      0.1.0
      source batch sha256
      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
      source defined aliases
        source span
        end
        308
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
        label id
        3657cc39-5ccd-49af-8f85-b622acc243d9
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
        start
        0
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
        spl effective date
        2026-06-25
        spl set id
        9c44bd5b-4464-40a4-8933-8680950f00f2
        spl version
        36
        structured fields status
        not_extracted_no_values_inferred_from_mentions
        structured indication
        age
        Source null
        approval pathway
        Source null
        biomarker and test
        Source null
        disease stage
        Source null
        limitations
        Source null
        line
        Source null
        prior therapy
        Source null
        regimen
        Source null
        tumor histology
        Source null
        use intent
        tumor_directed_candidate
        Passage 2 · unclassified context
        application numbers
        1. BLA761024
        brand names
        1. AMJEVITA
        classification reasons
        1. no_unambiguous_positive_indication_predicate
        clinical review status
        pending
        content role
        unclassified_context
        context span
        end
        659
        end exclusive
        true
        exact text
        ymptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and sy
        label id
        3657cc39-5ccd-49af-8f85-b622acc243d9
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
        start
        109
        current approval status
        not_reconciled
        duplicate text group
        dup-3de981b64eb086391ebe
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. ADALIMUMAB-ATTO
        id
        ind-span-806c1c5d08623eebcd96
        label id
        3657cc39-5ccd-49af-8f85-b622acc243d9
        positive predicate support span
        Source null
        qualifier mentions
        1. context exact
          ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
          kind
          age
          polarity
          not_inferred
          span
          end
          448
          end exclusive
          true
          exact text
          2 years of age
          label id
          3657cc39-5ccd-49af-8f85-b622acc243d9
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
          start
          434
        regulatory links
          schema version
          0.1.0
          source batch sha256
          fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
          source defined aliases
            source span
            end
            459
            end exclusive
            true
            exact text
            ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
            label id
            3657cc39-5ccd-49af-8f85-b622acc243d9
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
            start
            309
            source url
            https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
            spl effective date
            2026-06-25
            spl set id
            9c44bd5b-4464-40a4-8933-8680950f00f2
            spl version
            36
            structured fields status
            not_extracted_no_values_inferred_from_mentions
            structured indication
            age
            Source null
            approval pathway
            Source null
            biomarker and test
            Source null
            disease stage
            Source null
            limitations
            Source null
            line
            Source null
            prior therapy
            Source null
            regimen
            Source null
            tumor histology
            Source null
            use intent
            unclear
            Passage 3 · positive indication candidate
            application numbers
            1. BLA761024
            brand names
            1. AMJEVITA
            classification reasons
            1. inherited_predicate_from_same_label_section_requires_review
            2. no_tumor_directed_keyword_in_positive_statement
            clinical review status
            pending
            content role
            positive_indication_candidate
            context span
            end
            829
            end exclusive
            true
            exact text
            rately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years
            label id
            3657cc39-5ccd-49af-8f85-b622acc243d9
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
            start
            260
            current approval status
            not_reconciled
            duplicate text group
            dup-04490688d32029e3db6c
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. ADALIMUMAB-ATTO
            id
            ind-span-b375006db44c29ff7d5e
            label id
            3657cc39-5ccd-49af-8f85-b622acc243d9
            positive predicate support span
            end
            83
            end exclusive
            true
            exact text
            is a tumor necrosis factor (TNF) blocker indicated
            label id
            3657cc39-5ccd-49af-8f85-b622acc243d9
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
            start
            33
            qualifier mentions
            1. context exact
              on of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
              kind
              age
              polarity
              not_inferred
              span
              end
              595
              end exclusive
              true
              exact text
              adult patients
              label id
              3657cc39-5ccd-49af-8f85-b622acc243d9
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
              start
              581
            regulatory links
              schema version
              0.1.0
              source batch sha256
              fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
              source defined aliases
                source span
                end
                629
                end exclusive
                true
                exact text
                ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
                label id
                3657cc39-5ccd-49af-8f85-b622acc243d9
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                start
                460
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                spl effective date
                2026-06-25
                spl set id
                9c44bd5b-4464-40a4-8933-8680950f00f2
                spl version
                36
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                non_oncology_or_unclear_candidate
                Passage 4 · positive indication candidate
                application numbers
                1. BLA761024
                brand names
                1. AMJEVITA
                classification reasons
                1. inherited_predicate_from_same_label_section_requires_review
                2. no_tumor_directed_keyword_in_positive_statement
                clinical review status
                pending
                content role
                positive_indication_candidate
                context span
                end
                920
                end exclusive
                true
                exact text
                nts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
                label id
                3657cc39-5ccd-49af-8f85-b622acc243d9
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                start
                430
                current approval status
                not_reconciled
                duplicate text group
                dup-2cd105f288e111e28597
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. ADALIMUMAB-ATTO
                id
                ind-span-9b391cee8ef22b50a77c
                label id
                3657cc39-5ccd-49af-8f85-b622acc243d9
                positive predicate support span
                end
                83
                end exclusive
                true
                exact text
                is a tumor necrosis factor (TNF) blocker indicated
                label id
                3657cc39-5ccd-49af-8f85-b622acc243d9
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                start
                33
                qualifier mentions
                1. context exact
                  ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                  kind
                  age
                  polarity
                  not_inferred
                  span
                  end
                  683
                  end exclusive
                  true
                  exact text
                  adult patients
                  label id
                  3657cc39-5ccd-49af-8f85-b622acc243d9
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                  start
                  669
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                  source defined aliases
                    source span
                    end
                    720
                    end exclusive
                    true
                    exact text
                    ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                    label id
                    3657cc39-5ccd-49af-8f85-b622acc243d9
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                    start
                    630
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                    spl effective date
                    2026-06-25
                    spl set id
                    9c44bd5b-4464-40a4-8933-8680950f00f2
                    spl version
                    36
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    non_oncology_or_unclear_candidate
                    Passage 5 · positive indication candidate
                    application numbers
                    1. BLA761024
                    brand names
                    1. AMJEVITA
                    classification reasons
                    1. inherited_predicate_from_same_label_section_requires_review
                    2. no_tumor_directed_keyword_in_positive_statement
                    clinical review status
                    pending
                    content role
                    positive_indication_candidate
                    context span
                    end
                    1046
                    end exclusive
                    true
                    exact text
                    on of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or we
                    label id
                    3657cc39-5ccd-49af-8f85-b622acc243d9
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                    start
                    521
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-885773546f5fe5a72582
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. ADALIMUMAB-ATTO
                    id
                    ind-span-acf1f5740855d1bd0f9d
                    label id
                    3657cc39-5ccd-49af-8f85-b622acc243d9
                    positive predicate support span
                    end
                    83
                    end exclusive
                    true
                    exact text
                    is a tumor necrosis factor (TNF) blocker indicated
                    label id
                    3657cc39-5ccd-49af-8f85-b622acc243d9
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                    start
                    33
                    qualifier mentions
                    1. context exact
                      eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      797
                      end exclusive
                      true
                      exact text
                      adults
                      label id
                      3657cc39-5ccd-49af-8f85-b622acc243d9
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                      start
                      791
                    2. context exact
                      moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      820
                      end exclusive
                      true
                      exact text
                      pediatric patients
                      label id
                      3657cc39-5ccd-49af-8f85-b622acc243d9
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                      start
                      802
                    3. context exact
                      ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      835
                      end exclusive
                      true
                      exact text
                      6 years of age
                      label id
                      3657cc39-5ccd-49af-8f85-b622acc243d9
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                      start
                      821
                    regulatory links
                      schema version
                      0.1.0
                      source batch sha256
                      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                      source defined aliases
                        source span
                        end
                        846
                        end exclusive
                        true
                        exact text
                        ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                        label id
                        3657cc39-5ccd-49af-8f85-b622acc243d9
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                        start
                        721
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                        spl effective date
                        2026-06-25
                        spl set id
                        9c44bd5b-4464-40a4-8933-8680950f00f2
                        spl version
                        36
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        non_oncology_or_unclear_candidate
                        Passage 6 · unclassified context
                        application numbers
                        1. BLA761024
                        brand names
                        1. AMJEVITA
                        classification reasons
                        1. no_unambiguous_positive_indication_predicate
                        clinical review status
                        pending
                        content role
                        unclassified_context
                        context span
                        end
                        1135
                        end exclusive
                        true
                        exact text
                        signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
                        label id
                        3657cc39-5ccd-49af-8f85-b622acc243d9
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                        start
                        647
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-bb2f6ca3ede639284cad
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. ADALIMUMAB-ATTO
                        id
                        ind-span-6ca0af814cbd30dfef8c
                        label id
                        3657cc39-5ccd-49af-8f85-b622acc243d9
                        positive predicate support span
                        Source null
                        qualifier mentions
                        1. context exact
                          ment of moderately to severely active ulcerative colitis in adult patients.
                          kind
                          age
                          polarity
                          not_inferred
                          span
                          end
                          934
                          end exclusive
                          true
                          exact text
                          adult patients
                          label id
                          3657cc39-5ccd-49af-8f85-b622acc243d9
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                          start
                          920
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                          source defined aliases
                            source span
                            end
                            935
                            end exclusive
                            true
                            exact text
                            ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients.
                            label id
                            3657cc39-5ccd-49af-8f85-b622acc243d9
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                            start
                            847
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                            spl effective date
                            2026-06-25
                            spl set id
                            9c44bd5b-4464-40a4-8933-8680950f00f2
                            spl version
                            36
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            unclear
                            Passage 7 · limitation of use
                            application numbers
                            1. BLA761024
                            brand names
                            1. AMJEVITA
                            classification reasons
                            1. negative_or_not_established_clause
                            clinical review status
                            pending
                            content role
                            limitation_of_use
                            context span
                            end
                            1276
                            end exclusive
                            true
                            exact text
                            nt of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                            label id
                            3657cc39-5ccd-49af-8f85-b622acc243d9
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                            start
                            736
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-de029b4033b394d0523d
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. ADALIMUMAB-ATTO
                            id
                            ind-span-61da707b859157d368e5
                            label id
                            3657cc39-5ccd-49af-8f85-b622acc243d9
                            positive predicate support span
                            Source null
                            qualifier mentions
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                source defined aliases
                                  source span
                                  end
                                  1076
                                  end exclusive
                                  true
                                  exact text
                                  ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
                                  label id
                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                  start
                                  936
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                  spl effective date
                                  2026-06-25
                                  spl set id
                                  9c44bd5b-4464-40a4-8933-8680950f00f2
                                  spl version
                                  36
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  not_applicable
                                  Passage 8 · unclassified context
                                  application numbers
                                  1. BLA761024
                                  brand names
                                  1. AMJEVITA
                                  classification reasons
                                  1. no_unambiguous_positive_indication_predicate
                                  clinical review status
                                  pending
                                  content role
                                  unclassified_context
                                  context span
                                  end
                                  1476
                                  end exclusive
                                  true
                                  exact text
                                  y to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pedia
                                  label id
                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                  start
                                  877
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-7dab049befc3365f77eb
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. ADALIMUMAB-ATTO
                                  id
                                  ind-span-cf22284f6bf6fffcc7e8
                                  label id
                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                  1. context exact
                                    Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                    kind
                                    age
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1104
                                    end exclusive
                                    true
                                    exact text
                                    adult patients
                                    label id
                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                    start
                                    1090
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                    source defined aliases
                                      source span
                                      end
                                      1276
                                      end exclusive
                                      true
                                      exact text
                                      Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                      label id
                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                      start
                                      1077
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                      spl effective date
                                      2026-06-25
                                      spl set id
                                      9c44bd5b-4464-40a4-8933-8680950f00f2
                                      spl version
                                      36
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      unclear
                                      Passage 9 · unclassified context
                                      application numbers
                                      1. BLA761024
                                      brand names
                                      1. AMJEVITA
                                      classification reasons
                                      1. no_unambiguous_positive_indication_predicate
                                      clinical review status
                                      pending
                                      content role
                                      unclassified_context
                                      context span
                                      end
                                      1580
                                      end exclusive
                                      true
                                      exact text
                                      Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reduc
                                      label id
                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                      start
                                      1077
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-8828fd52e33558434a3e
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. ADALIMUMAB-ATTO
                                      id
                                      ind-span-9eaf1fba55c4f85919e7
                                      label id
                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                      positive predicate support span
                                      Source null
                                      qualifier mentions
                                      1. context exact
                                        of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                        kind
                                        age
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        1369
                                        end exclusive
                                        true
                                        exact text
                                        12 years of age
                                        label id
                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                        start
                                        1354
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                        source defined aliases
                                          source span
                                          end
                                          1380
                                          end exclusive
                                          true
                                          exact text
                                          ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                          label id
                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                          start
                                          1277
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                          spl effective date
                                          2026-06-25
                                          spl set id
                                          9c44bd5b-4464-40a4-8933-8680950f00f2
                                          spl version
                                          36
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          unclear
                                          Passage 10 · unclassified context
                                          application numbers
                                          1. BLA761024
                                          brand names
                                          1. AMJEVITA
                                          classification reasons
                                          1. no_unambiguous_positive_indication_predicate
                                          clinical review status
                                          pending
                                          content role
                                          unclassified_context
                                          context span
                                          end
                                          1715
                                          end exclusive
                                          true
                                          exact text
                                          emic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical funct
                                          label id
                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                          start
                                          1181
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-d2c62b9d88589dda8fc5
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. ADALIMUMAB-ATTO
                                          id
                                          ind-span-3013a2adff56621b2974
                                          label id
                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                          positive predicate support span
                                          Source null
                                          qualifier mentions
                                          1. context exact
                                            f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                            kind
                                            age
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            1466
                                            end exclusive
                                            true
                                            exact text
                                            adults
                                            label id
                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                            start
                                            1460
                                          2. context exact
                                            tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                            kind
                                            age
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            1489
                                            end exclusive
                                            true
                                            exact text
                                            pediatric patients
                                            label id
                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                            start
                                            1471
                                          3. context exact
                                            posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                            kind
                                            age
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            1504
                                            end exclusive
                                            true
                                            exact text
                                            2 years of age
                                            label id
                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                            start
                                            1490
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                            source defined aliases
                                              source span
                                              end
                                              1515
                                              end exclusive
                                              true
                                              exact text
                                              ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                              label id
                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                              start
                                              1381
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                              spl effective date
                                              2026-06-25
                                              spl set id
                                              9c44bd5b-4464-40a4-8933-8680950f00f2
                                              spl version
                                              36
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              unclear
                                              Passage 11 · unclassified context
                                              application numbers
                                              1. BLA761024
                                              brand names
                                              1. AMJEVITA
                                              classification reasons
                                              1. no_unambiguous_positive_indication_predicate
                                              clinical review status
                                              pending
                                              content role
                                              unclassified_context
                                              context span
                                              end
                                              1723
                                              end exclusive
                                              true
                                              exact text
                                              hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in a
                                              label id
                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                              start
                                              1316
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-acec029bc850a91864c4
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. ADALIMUMAB-ATTO
                                              id
                                              ind-span-94adf23a38c050448640
                                              label id
                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                              positive predicate support span
                                              Source null
                                              qualifier mentions
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                  source defined aliases
                                                    source span
                                                    end
                                                    1523
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ( 1.9 )
                                                    label id
                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                    start
                                                    1516
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                    spl effective date
                                                    2026-06-25
                                                    spl set id
                                                    9c44bd5b-4464-40a4-8933-8680950f00f2
                                                    spl version
                                                    36
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 12 · positive indication candidate
                                                    application numbers
                                                    1. BLA761024
                                                    brand names
                                                    1. AMJEVITA
                                                    classification reasons
                                                    1. explicit_positive_indication_predicate
                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                    clinical review status
                                                    pending
                                                    content role
                                                    positive_indication_candidate
                                                    context span
                                                    end
                                                    1993
                                                    end exclusive
                                                    true
                                                    exact text
                                                    nitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reduc
                                                    label id
                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                    start
                                                    1324
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-c51602a32a8d4d128a96
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. ADALIMUMAB-ATTO
                                                    id
                                                    ind-span-8ab698d1550931db7454
                                                    label id
                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                    positive predicate support span
                                                    end
                                                    1570
                                                    end exclusive
                                                    true
                                                    exact text
                                                    is indicated
                                                    label id
                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                    start
                                                    1558
                                                    qualifier mentions
                                                    1. context exact
                                                      on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                      kind
                                                      age
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1736
                                                      end exclusive
                                                      true
                                                      exact text
                                                      adult patients
                                                      label id
                                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                      start
                                                      1722
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                      source defined aliases
                                                        source span
                                                        end
                                                        1793
                                                        end exclusive
                                                        true
                                                        exact text
                                                        1.1 Rheumatoid Arthritis AMJEVITA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                        label id
                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                        start
                                                        1524
                                                        source url
                                                        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                        spl effective date
                                                        2026-06-25
                                                        spl set id
                                                        9c44bd5b-4464-40a4-8933-8680950f00f2
                                                        spl version
                                                        36
                                                        structured fields status
                                                        not_extracted_no_values_inferred_from_mentions
                                                        structured indication
                                                        age
                                                        Source null
                                                        approval pathway
                                                        Source null
                                                        biomarker and test
                                                        Source null
                                                        disease stage
                                                        Source null
                                                        limitations
                                                        Source null
                                                        line
                                                        Source null
                                                        prior therapy
                                                        Source null
                                                        regimen
                                                        Source null
                                                        tumor histology
                                                        Source null
                                                        use intent
                                                        non_oncology_or_unclear_candidate
                                                        Passage 13 · unclassified context
                                                        application numbers
                                                        1. BLA761024
                                                        brand names
                                                        1. AMJEVITA
                                                        classification reasons
                                                        1. no_unambiguous_positive_indication_predicate
                                                        clinical review status
                                                        pending
                                                        content role
                                                        unclassified_context
                                                        context span
                                                        end
                                                        2127
                                                        end exclusive
                                                        true
                                                        exact text
                                                        symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and old
                                                        label id
                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                        start
                                                        1594
                                                        current approval status
                                                        not_reconciled
                                                        duplicate text group
                                                        dup-831d85dd07b3e52d2148
                                                        extraction review status
                                                        automated_candidate_pending_source_review
                                                        generic names
                                                        1. ADALIMUMAB-ATTO
                                                        id
                                                        ind-span-2e7f42746217414142d6
                                                        label id
                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                        positive predicate support span
                                                        Source null
                                                        qualifier mentions
                                                        1. context exact
                                                          AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                          kind
                                                          biomarker
                                                          polarity
                                                          not_inferred
                                                          span
                                                          end
                                                          1887
                                                          end exclusive
                                                          true
                                                          exact text
                                                          methotrexate or other non-biologic disease-
                                                          label id
                                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                          start
                                                          1844
                                                        2. context exact
                                                          AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                          kind
                                                          regimen
                                                          polarity
                                                          not_inferred
                                                          span
                                                          end
                                                          1926
                                                          end exclusive
                                                          true
                                                          exact text
                                                          in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
                                                          label id
                                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                          start
                                                          1824
                                                        regulatory links
                                                          schema version
                                                          0.1.0
                                                          source batch sha256
                                                          fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                          source defined aliases
                                                            source span
                                                            end
                                                            1927
                                                            end exclusive
                                                            true
                                                            exact text
                                                            AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                            label id
                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                            start
                                                            1794
                                                            source url
                                                            https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                            spl effective date
                                                            2026-06-25
                                                            spl set id
                                                            9c44bd5b-4464-40a4-8933-8680950f00f2
                                                            spl version
                                                            36
                                                            structured fields status
                                                            not_extracted_no_values_inferred_from_mentions
                                                            structured indication
                                                            age
                                                            Source null
                                                            approval pathway
                                                            Source null
                                                            biomarker and test
                                                            Source null
                                                            disease stage
                                                            Source null
                                                            limitations
                                                            Source null
                                                            line
                                                            Source null
                                                            prior therapy
                                                            Source null
                                                            regimen
                                                            Source null
                                                            tumor histology
                                                            Source null
                                                            use intent
                                                            unclear
                                                            Passage 14 · positive indication candidate
                                                            application numbers
                                                            1. BLA761024
                                                            brand names
                                                            1. AMJEVITA
                                                            classification reasons
                                                            1. explicit_positive_indication_predicate
                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                            clinical review status
                                                            pending
                                                            content role
                                                            positive_indication_candidate
                                                            context span
                                                            end
                                                            2330
                                                            end exclusive
                                                            true
                                                            exact text
                                                            patients with moderately to severely active rheumatoid arthritis. AMJEVITA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. AMJEVITA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and imp
                                                            label id
                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                            start
                                                            1728
                                                            current approval status
                                                            not_reconciled
                                                            duplicate text group
                                                            dup-3d6483be2337168a6beb
                                                            extraction review status
                                                            automated_candidate_pending_source_review
                                                            generic names
                                                            1. ADALIMUMAB-ATTO
                                                            id
                                                            ind-span-e6dbe776f52e8fe00b02
                                                            label id
                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                            positive predicate support span
                                                            end
                                                            1983
                                                            end exclusive
                                                            true
                                                            exact text
                                                            is indicated
                                                            label id
                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                            start
                                                            1971
                                                            qualifier mentions
                                                            1. context exact
                                                              ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                              kind
                                                              age
                                                              polarity
                                                              not_inferred
                                                              span
                                                              end
                                                              2119
                                                              end exclusive
                                                              true
                                                              exact text
                                                              2 years of age
                                                              label id
                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                              start
                                                              2105
                                                            regulatory links
                                                              schema version
                                                              0.1.0
                                                              source batch sha256
                                                              fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                              source defined aliases
                                                                source span
                                                                end
                                                                2130
                                                                end exclusive
                                                                true
                                                                exact text
                                                                1.2 Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                                label id
                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                start
                                                                1928
                                                                source url
                                                                https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                spl effective date
                                                                2026-06-25
                                                                spl set id
                                                                9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                spl version
                                                                36
                                                                structured fields status
                                                                not_extracted_no_values_inferred_from_mentions
                                                                structured indication
                                                                age
                                                                Source null
                                                                approval pathway
                                                                Source null
                                                                biomarker and test
                                                                Source null
                                                                disease stage
                                                                Source null
                                                                limitations
                                                                Source null
                                                                line
                                                                Source null
                                                                prior therapy
                                                                Source null
                                                                regimen
                                                                Source null
                                                                tumor histology
                                                                Source null
                                                                use intent
                                                                non_oncology_or_unclear_candidate
                                                                Passage 15 · unclassified context
                                                                application numbers
                                                                1. BLA761024
                                                                brand names
                                                                1. AMJEVITA
                                                                classification reasons
                                                                1. no_unambiguous_positive_indication_predicate
                                                                clinical review status
                                                                pending
                                                                content role
                                                                unclassified_context
                                                                context span
                                                                end
                                                                2394
                                                                end exclusive
                                                                true
                                                                exact text
                                                                Juvenile Idiopathic Arthritis AMJEVITA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. AMJEVITA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic
                                                                label id
                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                start
                                                                1931
                                                                current approval status
                                                                not_reconciled
                                                                duplicate text group
                                                                dup-9213703bb222df18770a
                                                                extraction review status
                                                                automated_candidate_pending_source_review
                                                                generic names
                                                                1. ADALIMUMAB-ATTO
                                                                id
                                                                ind-span-dbec6630024f837723bd
                                                                label id
                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                positive predicate support span
                                                                Source null
                                                                qualifier mentions
                                                                1. context exact
                                                                  AMJEVITA can be used alone or in combination with methotrexate.
                                                                  kind
                                                                  biomarker
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2193
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  methotrexate
                                                                  label id
                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                  start
                                                                  2181
                                                                2. context exact
                                                                  AMJEVITA can be used alone or in combination with methotrexate.
                                                                  kind
                                                                  regimen
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2193
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  in combination with methotrexate
                                                                  label id
                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                  start
                                                                  2161
                                                                regulatory links
                                                                  schema version
                                                                  0.1.0
                                                                  source batch sha256
                                                                  fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                  source defined aliases
                                                                    source span
                                                                    end
                                                                    2194
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    AMJEVITA can be used alone or in combination with methotrexate.
                                                                    label id
                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                    start
                                                                    2131
                                                                    source url
                                                                    https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                    spl effective date
                                                                    2026-06-25
                                                                    spl set id
                                                                    9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                    spl version
                                                                    36
                                                                    structured fields status
                                                                    not_extracted_no_values_inferred_from_mentions
                                                                    structured indication
                                                                    age
                                                                    Source null
                                                                    approval pathway
                                                                    Source null
                                                                    biomarker and test
                                                                    Source null
                                                                    disease stage
                                                                    Source null
                                                                    limitations
                                                                    Source null
                                                                    line
                                                                    Source null
                                                                    prior therapy
                                                                    Source null
                                                                    regimen
                                                                    Source null
                                                                    tumor histology
                                                                    Source null
                                                                    use intent
                                                                    unclear
                                                                    Passage 16 · positive indication candidate
                                                                    application numbers
                                                                    1. BLA761024
                                                                    brand names
                                                                    1. AMJEVITA
                                                                    classification reasons
                                                                    1. explicit_positive_indication_predicate
                                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                                    clinical review status
                                                                    pending
                                                                    content role
                                                                    positive_indication_candidate
                                                                    context span
                                                                    end
                                                                    2605
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    g signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. AMJEVITA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. AMJEVITA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondy
                                                                    label id
                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                    start
                                                                    1995
                                                                    current approval status
                                                                    not_reconciled
                                                                    duplicate text group
                                                                    dup-2b45d58123dcff8f5d72
                                                                    extraction review status
                                                                    automated_candidate_pending_source_review
                                                                    generic names
                                                                    1. ADALIMUMAB-ATTO
                                                                    id
                                                                    ind-span-04322ef9d86397505af6
                                                                    label id
                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                    positive predicate support span
                                                                    end
                                                                    2240
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    is indicated
                                                                    label id
                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                    start
                                                                    2228
                                                                    qualifier mentions
                                                                    1. context exact
                                                                      on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                      kind
                                                                      age
                                                                      polarity
                                                                      not_inferred
                                                                      span
                                                                      end
                                                                      2372
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      adult patients
                                                                      label id
                                                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                      start
                                                                      2358
                                                                    regulatory links
                                                                      schema version
                                                                      0.1.0
                                                                      source batch sha256
                                                                      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                      source defined aliases
                                                                        source span
                                                                        end
                                                                        2405
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        1.3 Psoriatic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                        label id
                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                        start
                                                                        2195
                                                                        source url
                                                                        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                        spl effective date
                                                                        2026-06-25
                                                                        spl set id
                                                                        9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                        spl version
                                                                        36
                                                                        structured fields status
                                                                        not_extracted_no_values_inferred_from_mentions
                                                                        structured indication
                                                                        age
                                                                        Source null
                                                                        approval pathway
                                                                        Source null
                                                                        biomarker and test
                                                                        Source null
                                                                        disease stage
                                                                        Source null
                                                                        limitations
                                                                        Source null
                                                                        line
                                                                        Source null
                                                                        prior therapy
                                                                        Source null
                                                                        regimen
                                                                        Source null
                                                                        tumor histology
                                                                        Source null
                                                                        use intent
                                                                        non_oncology_or_unclear_candidate
                                                                        Passage 17 · unclassified context
                                                                        application numbers
                                                                        1. BLA761024
                                                                        brand names
                                                                        1. AMJEVITA
                                                                        classification reasons
                                                                        1. no_unambiguous_positive_indication_predicate
                                                                        clinical review status
                                                                        pending
                                                                        content role
                                                                        unclassified_context
                                                                        context span
                                                                        end
                                                                        2676
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        ic Arthritis AMJEVITA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. AMJEVITA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of m
                                                                        label id
                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                        start
                                                                        2206
                                                                        current approval status
                                                                        not_reconciled
                                                                        duplicate text group
                                                                        dup-27329b4167e777e52885
                                                                        extraction review status
                                                                        automated_candidate_pending_source_review
                                                                        generic names
                                                                        1. ADALIMUMAB-ATTO
                                                                        id
                                                                        ind-span-59d52ec47c7257b877b0
                                                                        label id
                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                        positive predicate support span
                                                                        Source null
                                                                        qualifier mentions
                                                                        1. context exact
                                                                          AMJEVITA can be used alone or in combination with non-biologic DMARDs.
                                                                          kind
                                                                          regimen
                                                                          polarity
                                                                          not_inferred
                                                                          span
                                                                          end
                                                                          2475
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          in combination with non-biologic DMARDs
                                                                          label id
                                                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                          start
                                                                          2436
                                                                        regulatory links
                                                                          schema version
                                                                          0.1.0
                                                                          source batch sha256
                                                                          fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                          source defined aliases
                                                                            source span
                                                                            end
                                                                            2476
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            AMJEVITA can be used alone or in combination with non-biologic DMARDs.
                                                                            label id
                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                            start
                                                                            2406
                                                                            source url
                                                                            https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                            spl effective date
                                                                            2026-06-25
                                                                            spl set id
                                                                            9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                            spl version
                                                                            36
                                                                            structured fields status
                                                                            not_extracted_no_values_inferred_from_mentions
                                                                            structured indication
                                                                            age
                                                                            Source null
                                                                            approval pathway
                                                                            Source null
                                                                            biomarker and test
                                                                            Source null
                                                                            disease stage
                                                                            Source null
                                                                            limitations
                                                                            Source null
                                                                            line
                                                                            Source null
                                                                            prior therapy
                                                                            Source null
                                                                            regimen
                                                                            Source null
                                                                            tumor histology
                                                                            Source null
                                                                            use intent
                                                                            unclear
                                                                            Passage 18 · positive indication candidate
                                                                            application numbers
                                                                            1. BLA761024
                                                                            brand names
                                                                            1. AMJEVITA
                                                                            classification reasons
                                                                            1. explicit_positive_indication_predicate
                                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                                            clinical review status
                                                                            pending
                                                                            content role
                                                                            positive_indication_candidate
                                                                            context span
                                                                            end
                                                                            2811
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            ibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. AMJEVITA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA
                                                                            label id
                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                            start
                                                                            2277
                                                                            current approval status
                                                                            not_reconciled
                                                                            duplicate text group
                                                                            dup-f056f4ad55ecf723244b
                                                                            extraction review status
                                                                            automated_candidate_pending_source_review
                                                                            generic names
                                                                            1. ADALIMUMAB-ATTO
                                                                            id
                                                                            ind-span-7790d7d0c20e1f3aee38
                                                                            label id
                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                            positive predicate support span
                                                                            end
                                                                            2525
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            is indicated
                                                                            label id
                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                            start
                                                                            2513
                                                                            qualifier mentions
                                                                            1. context exact
                                                                              is AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                              kind
                                                                              age
                                                                              polarity
                                                                              not_inferred
                                                                              span
                                                                              end
                                                                              2575
                                                                              end exclusive
                                                                              true
                                                                              exact text
                                                                              adult patients
                                                                              label id
                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                              offset unit
                                                                              unicode_code_points
                                                                              source array index
                                                                              0
                                                                              source field
                                                                              indications_and_usage_exact
                                                                              source text sha256
                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                              start
                                                                              2561
                                                                            regulatory links
                                                                              schema version
                                                                              0.1.0
                                                                              source batch sha256
                                                                              fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                              source defined aliases
                                                                                source span
                                                                                end
                                                                                2611
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                                label id
                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                start
                                                                                2477
                                                                                source url
                                                                                https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                spl effective date
                                                                                2026-06-25
                                                                                spl set id
                                                                                9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                spl version
                                                                                36
                                                                                structured fields status
                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                structured indication
                                                                                age
                                                                                Source null
                                                                                approval pathway
                                                                                Source null
                                                                                biomarker and test
                                                                                Source null
                                                                                disease stage
                                                                                Source null
                                                                                limitations
                                                                                Source null
                                                                                line
                                                                                Source null
                                                                                prior therapy
                                                                                Source null
                                                                                regimen
                                                                                Source null
                                                                                tumor histology
                                                                                Source null
                                                                                use intent
                                                                                non_oncology_or_unclear_candidate
                                                                                Passage 19 · positive indication candidate
                                                                                application numbers
                                                                                1. BLA761024
                                                                                brand names
                                                                                1. AMJEVITA
                                                                                classification reasons
                                                                                1. explicit_positive_indication_predicate
                                                                                2. no_tumor_directed_keyword_in_positive_statement
                                                                                clinical review status
                                                                                pending
                                                                                content role
                                                                                positive_indication_candidate
                                                                                context span
                                                                                end
                                                                                2979
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                TA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis AMJEVITA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has n
                                                                                label id
                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                start
                                                                                2412
                                                                                current approval status
                                                                                not_reconciled
                                                                                duplicate text group
                                                                                dup-f7e7f6ce89b2c6ada44b
                                                                                extraction review status
                                                                                automated_candidate_pending_source_review
                                                                                generic names
                                                                                1. ADALIMUMAB-ATTO
                                                                                id
                                                                                ind-span-949ec44b065ef8b14809
                                                                                label id
                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                positive predicate support span
                                                                                end
                                                                                2653
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                is indicated
                                                                                label id
                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                start
                                                                                2641
                                                                                qualifier mentions
                                                                                1. context exact
                                                                                  eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2730
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  adults
                                                                                  label id
                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                  start
                                                                                  2724
                                                                                2. context exact
                                                                                  moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2753
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  pediatric patients
                                                                                  label id
                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                  start
                                                                                  2735
                                                                                3. context exact
                                                                                  ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2768
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  6 years of age
                                                                                  label id
                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                  start
                                                                                  2754
                                                                                regulatory links
                                                                                  schema version
                                                                                  0.1.0
                                                                                  source batch sha256
                                                                                  fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                  source defined aliases
                                                                                    source span
                                                                                    end
                                                                                    2779
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                    label id
                                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                    start
                                                                                    2612
                                                                                    source url
                                                                                    https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                    spl effective date
                                                                                    2026-06-25
                                                                                    spl set id
                                                                                    9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                    spl version
                                                                                    36
                                                                                    structured fields status
                                                                                    not_extracted_no_values_inferred_from_mentions
                                                                                    structured indication
                                                                                    age
                                                                                    Source null
                                                                                    approval pathway
                                                                                    Source null
                                                                                    biomarker and test
                                                                                    Source null
                                                                                    disease stage
                                                                                    Source null
                                                                                    limitations
                                                                                    Source null
                                                                                    line
                                                                                    Source null
                                                                                    prior therapy
                                                                                    Source null
                                                                                    regimen
                                                                                    Source null
                                                                                    tumor histology
                                                                                    Source null
                                                                                    use intent
                                                                                    non_oncology_or_unclear_candidate
                                                                                    Passage 20 · positive indication candidate
                                                                                    application numbers
                                                                                    1. BLA761024
                                                                                    brand names
                                                                                    1. AMJEVITA
                                                                                    classification reasons
                                                                                    1. explicit_positive_indication_predicate
                                                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                                                    clinical review status
                                                                                    pending
                                                                                    content role
                                                                                    positive_indication_candidate
                                                                                    context span
                                                                                    end
                                                                                    3113
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    active ankylosing spondylitis. 1.5 Crohn's Disease AMJEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] . 1.7 Plaq
                                                                                    label id
                                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                    start
                                                                                    2580
                                                                                    current approval status
                                                                                    not_reconciled
                                                                                    duplicate text group
                                                                                    dup-88dab1a3814c272277ee
                                                                                    extraction review status
                                                                                    automated_candidate_pending_source_review
                                                                                    generic names
                                                                                    1. ADALIMUMAB-ATTO
                                                                                    id
                                                                                    ind-span-d9dab16b06d3fa04a740
                                                                                    label id
                                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                    positive predicate support span
                                                                                    end
                                                                                    2824
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    is indicated
                                                                                    label id
                                                                                    3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                    start
                                                                                    2812
                                                                                    qualifier mentions
                                                                                    1. context exact
                                                                                      ment of moderately to severely active ulcerative colitis in adult patients.
                                                                                      kind
                                                                                      age
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      2912
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      adult patients
                                                                                      label id
                                                                                      3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                      start
                                                                                      2898
                                                                                    regulatory links
                                                                                      schema version
                                                                                      0.1.0
                                                                                      source batch sha256
                                                                                      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                      source defined aliases
                                                                                        source span
                                                                                        end
                                                                                        2913
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
                                                                                        label id
                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                        start
                                                                                        2780
                                                                                        source url
                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                        spl effective date
                                                                                        2026-06-25
                                                                                        spl set id
                                                                                        9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                        spl version
                                                                                        36
                                                                                        structured fields status
                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                        structured indication
                                                                                        age
                                                                                        Source null
                                                                                        approval pathway
                                                                                        Source null
                                                                                        biomarker and test
                                                                                        Source null
                                                                                        disease stage
                                                                                        Source null
                                                                                        limitations
                                                                                        Source null
                                                                                        line
                                                                                        Source null
                                                                                        prior therapy
                                                                                        Source null
                                                                                        regimen
                                                                                        Source null
                                                                                        tumor histology
                                                                                        Source null
                                                                                        use intent
                                                                                        non_oncology_or_unclear_candidate
                                                                                        Passage 21 · limitation of use
                                                                                        application numbers
                                                                                        1. BLA761024
                                                                                        brand names
                                                                                        1. AMJEVITA
                                                                                        classification reasons
                                                                                        1. negative_or_not_established_clause
                                                                                        clinical review status
                                                                                        pending
                                                                                        content role
                                                                                        limitation_of_use
                                                                                        context span
                                                                                        end
                                                                                        3304
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        isease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis AMJEVITA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] . 1.7 Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other
                                                                                        label id
                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                        start
                                                                                        2714
                                                                                        current approval status
                                                                                        not_reconciled
                                                                                        duplicate text group
                                                                                        dup-e7a5a46aa0d2310aebc0
                                                                                        extraction review status
                                                                                        automated_candidate_pending_source_review
                                                                                        generic names
                                                                                        1. ADALIMUMAB-ATTO
                                                                                        id
                                                                                        ind-span-94f93fbb8c56bdbd7e5a
                                                                                        label id
                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                        positive predicate support span
                                                                                        Source null
                                                                                        qualifier mentions
                                                                                          regulatory links
                                                                                            schema version
                                                                                            0.1.0
                                                                                            source batch sha256
                                                                                            fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                            source defined aliases
                                                                                              source span
                                                                                              end
                                                                                              3104
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] .
                                                                                              label id
                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                              start
                                                                                              2914
                                                                                              source url
                                                                                              https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                              spl effective date
                                                                                              2026-06-25
                                                                                              spl set id
                                                                                              9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                              spl version
                                                                                              36
                                                                                              structured fields status
                                                                                              not_extracted_no_values_inferred_from_mentions
                                                                                              structured indication
                                                                                              age
                                                                                              Source null
                                                                                              approval pathway
                                                                                              Source null
                                                                                              biomarker and test
                                                                                              Source null
                                                                                              disease stage
                                                                                              Source null
                                                                                              limitations
                                                                                              Source null
                                                                                              line
                                                                                              Source null
                                                                                              prior therapy
                                                                                              Source null
                                                                                              regimen
                                                                                              Source null
                                                                                              tumor histology
                                                                                              Source null
                                                                                              use intent
                                                                                              not_applicable
                                                                                              Passage 22 · positive indication candidate
                                                                                              application numbers
                                                                                              1. BLA761024
                                                                                              brand names
                                                                                              1. AMJEVITA
                                                                                              classification reasons
                                                                                              1. explicit_positive_indication_predicate
                                                                                              2. no_tumor_directed_keyword_in_positive_statement
                                                                                              clinical review status
                                                                                              pending
                                                                                              content role
                                                                                              positive_indication_candidate
                                                                                              context span
                                                                                              end
                                                                                              3555
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              atients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ] . 1.7 Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AM
                                                                                              label id
                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                              start
                                                                                              2905
                                                                                              current approval status
                                                                                              not_reconciled
                                                                                              duplicate text group
                                                                                              dup-cd99538d598e436d5cb9
                                                                                              extraction review status
                                                                                              automated_candidate_pending_source_review
                                                                                              generic names
                                                                                              1. ADALIMUMAB-ATTO
                                                                                              id
                                                                                              ind-span-56d0e7522e5ecf6e219b
                                                                                              label id
                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                              positive predicate support span
                                                                                              end
                                                                                              3147
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              is indicated
                                                                                              label id
                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                              start
                                                                                              3135
                                                                                              qualifier mentions
                                                                                              1. context exact
                                                                                                Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                                                                                kind
                                                                                                age
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                3183
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                adult patients
                                                                                                label id
                                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                start
                                                                                                3169
                                                                                              regulatory links
                                                                                                schema version
                                                                                                0.1.0
                                                                                                source batch sha256
                                                                                                fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                                source defined aliases
                                                                                                  source span
                                                                                                  end
                                                                                                  3355
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  1.7 Plaque Psoriasis AMJEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                                                                                  label id
                                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                  start
                                                                                                  3105
                                                                                                  source url
                                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                                  spl effective date
                                                                                                  2026-06-25
                                                                                                  spl set id
                                                                                                  9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                                  spl version
                                                                                                  36
                                                                                                  structured fields status
                                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                                  structured indication
                                                                                                  age
                                                                                                  Source null
                                                                                                  approval pathway
                                                                                                  Source null
                                                                                                  biomarker and test
                                                                                                  Source null
                                                                                                  disease stage
                                                                                                  Source null
                                                                                                  limitations
                                                                                                  Source null
                                                                                                  line
                                                                                                  Source null
                                                                                                  prior therapy
                                                                                                  Source null
                                                                                                  regimen
                                                                                                  Source null
                                                                                                  tumor histology
                                                                                                  Source null
                                                                                                  use intent
                                                                                                  non_oncology_or_unclear_candidate
                                                                                                  Passage 23 · risk or warning
                                                                                                  application numbers
                                                                                                  1. BLA761024
                                                                                                  brand names
                                                                                                  1. AMJEVITA
                                                                                                  classification reasons
                                                                                                  1. risk_or_warning_words_without_positive_predicate
                                                                                                  clinical review status
                                                                                                  pending
                                                                                                  content role
                                                                                                  risk_or_warning
                                                                                                  context span
                                                                                                  end
                                                                                                  3723
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis AMJEVITA is indicated for the tr
                                                                                                  label id
                                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                  start
                                                                                                  3156
                                                                                                  current approval status
                                                                                                  not_reconciled
                                                                                                  duplicate text group
                                                                                                  dup-25bef8346ad741f166f4
                                                                                                  extraction review status
                                                                                                  automated_candidate_pending_source_review
                                                                                                  generic names
                                                                                                  1. ADALIMUMAB-ATTO
                                                                                                  id
                                                                                                  ind-span-d587705a7a953493bd8c
                                                                                                  label id
                                                                                                  3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                  positive predicate support span
                                                                                                  Source null
                                                                                                  qualifier mentions
                                                                                                    regulatory links
                                                                                                      schema version
                                                                                                      0.1.0
                                                                                                      source batch sha256
                                                                                                      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                                      source defined aliases
                                                                                                        source span
                                                                                                        end
                                                                                                        3523
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] .
                                                                                                        label id
                                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                        start
                                                                                                        3356
                                                                                                        source url
                                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                                        spl effective date
                                                                                                        2026-06-25
                                                                                                        spl set id
                                                                                                        9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                                        spl version
                                                                                                        36
                                                                                                        structured fields status
                                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                                        structured indication
                                                                                                        age
                                                                                                        Source null
                                                                                                        approval pathway
                                                                                                        Source null
                                                                                                        biomarker and test
                                                                                                        Source null
                                                                                                        disease stage
                                                                                                        Source null
                                                                                                        limitations
                                                                                                        Source null
                                                                                                        line
                                                                                                        Source null
                                                                                                        prior therapy
                                                                                                        Source null
                                                                                                        regimen
                                                                                                        Source null
                                                                                                        tumor histology
                                                                                                        Source null
                                                                                                        use intent
                                                                                                        not_applicable
                                                                                                        Passage 24 · positive indication candidate
                                                                                                        application numbers
                                                                                                        1. BLA761024
                                                                                                        brand names
                                                                                                        1. AMJEVITA
                                                                                                        classification reasons
                                                                                                        1. explicit_positive_indication_predicate
                                                                                                        2. no_tumor_directed_keyword_in_positive_statement
                                                                                                        clinical review status
                                                                                                        pending
                                                                                                        content role
                                                                                                        positive_indication_candidate
                                                                                                        context span
                                                                                                        end
                                                                                                        3847
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        are medically less appropriate. AMJEVITA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis AMJEVITA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                        label id
                                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                        start
                                                                                                        3324
                                                                                                        current approval status
                                                                                                        not_reconciled
                                                                                                        duplicate text group
                                                                                                        dup-eb0512a160a6717343fa
                                                                                                        extraction review status
                                                                                                        automated_candidate_pending_source_review
                                                                                                        generic names
                                                                                                        1. ADALIMUMAB-ATTO
                                                                                                        id
                                                                                                        ind-span-25897bded86c9cb5a5a4
                                                                                                        label id
                                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                        positive predicate support span
                                                                                                        end
                                                                                                        3574
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        is indicated
                                                                                                        label id
                                                                                                        3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                        start
                                                                                                        3562
                                                                                                        qualifier mentions
                                                                                                        1. context exact
                                                                                                          of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                                                                                          kind
                                                                                                          age
                                                                                                          polarity
                                                                                                          not_inferred
                                                                                                          span
                                                                                                          end
                                                                                                          3667
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          12 years of age
                                                                                                          label id
                                                                                                          3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                          start
                                                                                                          3652
                                                                                                        regulatory links
                                                                                                          schema version
                                                                                                          0.1.0
                                                                                                          source batch sha256
                                                                                                          fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                                          source defined aliases
                                                                                                            source span
                                                                                                            end
                                                                                                            3678
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                                                                                            label id
                                                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                            start
                                                                                                            3524
                                                                                                            source url
                                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                                            spl effective date
                                                                                                            2026-06-25
                                                                                                            spl set id
                                                                                                            9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                                            spl version
                                                                                                            36
                                                                                                            structured fields status
                                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                                            structured indication
                                                                                                            age
                                                                                                            Source null
                                                                                                            approval pathway
                                                                                                            Source null
                                                                                                            biomarker and test
                                                                                                            Source null
                                                                                                            disease stage
                                                                                                            Source null
                                                                                                            limitations
                                                                                                            Source null
                                                                                                            line
                                                                                                            Source null
                                                                                                            prior therapy
                                                                                                            Source null
                                                                                                            regimen
                                                                                                            Source null
                                                                                                            tumor histology
                                                                                                            Source null
                                                                                                            use intent
                                                                                                            non_oncology_or_unclear_candidate
                                                                                                            Passage 25 · positive indication candidate
                                                                                                            application numbers
                                                                                                            1. BLA761024
                                                                                                            brand names
                                                                                                            1. AMJEVITA
                                                                                                            classification reasons
                                                                                                            1. explicit_positive_indication_predicate
                                                                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                                                                            clinical review status
                                                                                                            pending
                                                                                                            content role
                                                                                                            positive_indication_candidate
                                                                                                            context span
                                                                                                            end
                                                                                                            3847
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            sician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa AMJEVITA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis AMJEVITA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                            label id
                                                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                            start
                                                                                                            3479
                                                                                                            current approval status
                                                                                                            not_reconciled
                                                                                                            duplicate text group
                                                                                                            dup-0d96f44c4a6299d7c89e
                                                                                                            extraction review status
                                                                                                            automated_candidate_pending_source_review
                                                                                                            generic names
                                                                                                            1. ADALIMUMAB-ATTO
                                                                                                            id
                                                                                                            ind-span-c8ec252e05f9996e740d
                                                                                                            label id
                                                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                            positive predicate support span
                                                                                                            end
                                                                                                            3712
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            is indicated
                                                                                                            label id
                                                                                                            3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                            start
                                                                                                            3700
                                                                                                            qualifier mentions
                                                                                                            1. context exact
                                                                                                              f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                              kind
                                                                                                              age
                                                                                                              polarity
                                                                                                              not_inferred
                                                                                                              span
                                                                                                              end
                                                                                                              3798
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              adults
                                                                                                              label id
                                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                              start
                                                                                                              3792
                                                                                                            2. context exact
                                                                                                              tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                              kind
                                                                                                              age
                                                                                                              polarity
                                                                                                              not_inferred
                                                                                                              span
                                                                                                              end
                                                                                                              3821
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              pediatric patients
                                                                                                              label id
                                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                              start
                                                                                                              3803
                                                                                                            3. context exact
                                                                                                              posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                              kind
                                                                                                              age
                                                                                                              polarity
                                                                                                              not_inferred
                                                                                                              span
                                                                                                              end
                                                                                                              3836
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              2 years of age
                                                                                                              label id
                                                                                                              3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                              start
                                                                                                              3822
                                                                                                            regulatory links
                                                                                                              schema version
                                                                                                              0.1.0
                                                                                                              source batch sha256
                                                                                                              fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                                                                                                              source defined aliases
                                                                                                                source span
                                                                                                                end
                                                                                                                3847
                                                                                                                end exclusive
                                                                                                                true
                                                                                                                exact text
                                                                                                                1.9 Uveitis AMJEVITA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                label id
                                                                                                                3657cc39-5ccd-49af-8f85-b622acc243d9
                                                                                                                offset unit
                                                                                                                unicode_code_points
                                                                                                                source array index
                                                                                                                0
                                                                                                                source field
                                                                                                                indications_and_usage_exact
                                                                                                                source text sha256
                                                                                                                8bf60d129058d4ed8b46751e9e3998c6feed9cbb89573d5c7e1e9d92491e9112
                                                                                                                start
                                                                                                                3679
                                                                                                                source url
                                                                                                                https://api.fda.gov/drug/label.json?search=id%3A%223657cc39-5ccd-49af-8f85-b622acc243d9%22
                                                                                                                spl effective date
                                                                                                                2026-06-25
                                                                                                                spl set id
                                                                                                                9c44bd5b-4464-40a4-8933-8680950f00f2
                                                                                                                spl version
                                                                                                                36
                                                                                                                structured fields status
                                                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                                                structured indication
                                                                                                                age
                                                                                                                Source null
                                                                                                                approval pathway
                                                                                                                Source null
                                                                                                                biomarker and test
                                                                                                                Source null
                                                                                                                disease stage
                                                                                                                Source null
                                                                                                                limitations
                                                                                                                Source null
                                                                                                                line
                                                                                                                Source null
                                                                                                                prior therapy
                                                                                                                Source null
                                                                                                                regimen
                                                                                                                Source null
                                                                                                                tumor histology
                                                                                                                Source null
                                                                                                                use intent
                                                                                                                non_oncology_or_unclear_candidate

                                                                                                                Preserved source evidence · Not medical advice